The coronavirus pandemic brought global renown to the mRNA technology that underpins vaccines from Pfizer/BioNTech and Moderna, and on Monday earned a Nobel Prize for two scientists who have been key to its development.
Katalin Kariko of Hungary and Drew Weissman of the United States won the Nobel Medicine Prize for their work on "nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19".
These types of jabs are new but researchers have been working for decades to try to figure out how to use messenger RNA (ribonucleic acid) for other vaccinations and to treat illnesses from AIDS to cancer.
In the case of the Pfizer/BioNTech and Moderna jabs, lab-generated mRNA tells human cells to create antigens—proteins that are similar to ones found in the Covid-19 virus.
Thanks to those antigens, a person"s immune system learns how to fight the virus and neutralise Covid if it enters the body.
After the cells create these proteins, the body breaks down the mRNA instructions and gets rid of them.
Such direct communication with cells is revolutionary—classic vaccines aimed to provoke an immune response by injecting a neutralised form of a virus or antigens into the system.
A decade later, scientists were able to get the same results in mice, but mRNA still had two major drawbacks as a medical tool.
For one thing, cells in live animals resisted synthetic mRNA, provoking a dangerous immune response.
On top of that, mRNA molecules are fragile, making them difficult to deliver to the system without altering them.
In 2005, Kariko and Weissman of Penn State University published a groundbreaking study showing that a lipid—or fat molecule—envelope could safely deliver mRNA without negative effects.
The research caused a buzz in the pharmaceutical community and start-ups dedicated to mRNA therapies began to pop up around the world.
Researchers have also started testing personalised treatments on cancer patients, using samples of the proteins in their tumours to create specialised mRNA.
This then triggers the immune system to target specific cancer cells.
"The mRNA platform is versatile," University of Pennsylvania biochemist Norbert Pardi told AFP. "Any protein can be encoded as mRNA so there are many potential applications."
First Published: Oct 03, 2023, 16:58
Subscribe Now